Table 2 Details of studies for patients with ARDS
From: The influence of steroid type on outcomes in patients with acute respiratory distress syndrome
Author year | No of patients steroid/control | Main etiology | Initiation timing of steroids after the diagnosis of ARDS | Regimen of steroids | Comparison | Planned primary outcome |
|---|---|---|---|---|---|---|
Steinberg 2006 [18] | 89/91 | Pneumonia 42% (76/180) Sepsis 22% (40/180) | 7–24 days | Methylprednisolone Loading: 2 mg/kg Day1–14: 0.5 mg 4 times daily Day15–21: 0.5 mg 2 times daily Tapering off over 4 days | Placebo (5% dextrose) | Mortality at day 60 |
Meduri 2007 [19] | 63/28 | Pneumonia 42% (38/91) Sepsis 16% (15/91) | Less than 72 h | Methylprednisolone Loading: 1 mg/kg Day1–14: 1 Day15–21: 0.5 Day22–25: 0.25 Day26–28: 0.125 mg/kg/day by continuous infusions | Placebo (0.9% serine) | 1-point reduction in lung injury score |
Tongyoo 2016 [13] | 98/99 | Pneumonia 51% (100/197) | Less than 12 h | Hydrocortisone Day1–7: 50 mg 6 times daily | Placebo (Not detail) | No |
Tomazini 2020 [4] | 151/148 | Pneumonia due to COVID-19 | Less than 24 h | Dexamethasone Day1–5: 20 Day6–10: 10 mg once daily | No placebo | Ventilator-free days to day 28 |
Villar 2020 [16] | 139/138 | Pneumonia 53% (147/277) Sepsis 24% (67/277) | Less than 24 h | Dexamethasone Day1–5: 20 Day6–10: 10 mg once daily | No placebo | Ventilator-free days to day 28 |
Edalatifard 2020 [21] | 34/28 | Pneumonia due to COVID-19 | 24–48 h | Methylprednisolone 250 mg 3 days | No placebo | Radiographic findings Mortality (Not detail of observational period), etc. |